The Federal Research and Clinical Center of Physical-Chemical Medicine (SRI PCM) of the Federal Medical Biological Agency (FMBA) has presented new chips and reagents for the Indicator-BIO device. They enable the detection of dangerous viruses, including the novel coronavirus COVID-19, in biological fluids in 15 minutes. The Indicator-BIO analyzer was developed by specialists from the Troitsk Research and Development Center, a part of the TechnoSpark Group of Companies, which is a subsidiary of the Fund for Infrastructure and Educational Programs of the RUSNANO Group. Earlier Indicator-BIO was presented to Veronika Skvortsova, Head of the Federal Medical and Biological Agency.
The main advantage of the Indicator-BIO analyzer prototype, which has earlier been presented by RUSNANO, is its capability to handle different reagents. The new reagents were promptly developed by the Russian scientists engaged by the FMBA, and it is thanks to these reagents that the time of obtaining a test result has been halved.
The RUSNANO group is ready to involve the entire potential of the developers and engineers of its companies for combating the COVID-19 pandemic.
“Today the PCR diagnostics is the quickest method of detecting infectious diseases, which has already proven its efficiency. The Troitsk nano-center managed to develop a device, which made it possible to many-fold decrease the test time to mere 15 minutes. Moreover, the device does not require a specially equipped laboratory,” said Anatoly Chubais, Chairman of the Board of RUSNANO Managing Company and the Fund for Infrastructure and Educational Programs.
“We understand the challenge we face today as scientists and developers: we need extremely accurate, quick and simple express analyzers. In response to this challenge, in just a couple of weeks, my colleagues from SRI PCM FMBA and I found a way to simplify and shrink the procedure for bio-material preparing and subsequent analysis to 15-20 minutes. Such portable device has no counterparts, especially if to consider the test cost. We will soon receive a medical item registration certificate for the device and reagents,” said Yevgeny Gorsky, TRDC CEO.
“Our device enables decreasing the time of a COVID-19 test. However, it is not the only important thing to us in today’s crisis situation. Equally crucial factor is the speed of deploying the production of the equipment that is so much necessary for combating the virus. While one of our developer startups is testing and improving the device, another startup is launching the production of some of the device parts – the optics with appropriate coating, the third one is providing professional assistance with the registration certificate procedures, the fourth one is at the final stage of designing the device interface, and, even before the official procedures are completed, the fifth one is already negotiating parts delivery for the device serial production. When it comes to launching new technological products, the labor division system, developed by TechnoSpark in the last eight years, works as a quick and efficient innovation conveyor,” said Denis Kovalevich, CEO of the TechnoSpark Group of Companies.
Let us remind that the Indicator-BIO analyzer is capable of detecting up to four pathogens at the same time by means of polymerase chain reaction (PCR), which is a high-precision method of molecular and genetic diagnostics. In addition, a range of testing systems was developed in the form of microfluidic cartridges, including the ones for detecting the novel coronavirus SARS-CoV-2.